New therapeutic targets in stroke prevention: the effect of allopurinol on the cerebral vasculature of patients with subcortical stroke

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001669-33-GB

Enrollment

Registered

2005-10-13

Start date

2005-12-09

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subcortical Ischaemic Stroke

Interventions

Trade Name: Allopurinol Product Name: Allopurinol Product Code: Allopurinol Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subcortical ischaemic stroke 2. Index stroke between two weeks and three months prior to randomisation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. >70% extra-cranial internal carotid artery stenosis 2. Known coronary arterial disease 3. Significant co-morbidity 4. Contra-indication to or indication for administration of allopurinol 5. Contra-indication to administration of acetazolamide 6. Concurrent azathioprine or 6-mercaptopurine therapy 7. Serum creatinine concentration greater than 250 micromoles per litre

Design outcomes

Primary

Measure	Time frame
Main Objective: To assess whether impaired basal cerebral vasomotor reactivity (as assessed by increased mean velocity of middle cerebral artery blood flow following acetazolamide infusion) in patients with subcortical stroke is improved by intervention with allopurinol.;Secondary Objective: To assess the effect of pharmacologic intervention with allopurinol in these patients on circulating indices of endothelial function, including CRP, vWF TPA PAI-1 and VEGF. To assess clincal endpoints.;Primary end point(s): The variable used for comparison between treatments will be the change in MCA velocity induced by the acetazolamide infusion.	—

Measure

Time frame

Main Objective: To assess whether impaired basal cerebral vasomotor reactivity (as assessed by increased mean velocity of middle cerebral artery blood flow following acetazolamide infusion) in patients with subcortical stroke is improved by intervention with allopurinol.;Secondary Objective: To assess the effect of pharmacologic intervention with allopurinol in these patients on circulating indices of endothelial function, including CRP, vWF TPA PAI-1 and VEGF. To assess clincal endpoints.;Primary end point(s): The variable used for comparison between treatments will be the change in MCA velocity induced by the acetazolamide infusion.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026